Nuwellis, Inc.
NUWENasdaq
$2.85
↓ -3.1%Jul 17 close · end-of-day
Price
1Y↓ -99.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$5.9M
Enterprise Value
$3.8M
P/E
2.1
P/S
0.7
P/B
2.2
EV/EBITDA
—
PEG
—
FCF Yield
-194.6%
Dividend Yield
—
Revenue (TTM)
$8.8M
Net Income (TTM)
-$19.0M
Free Cash Flow (TTM)
-$11.5M
Gross Margin
65.5%
Operating Margin
-143.8%
Net Margin
-217.2%
ROE
-715.8%
ROIC
-1724.1%
Debt / Equity
—
Net Cash
$2.1M
Return 1Y
-99.5%
Company profile
Nuwellis, Inc. focuses on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy. Its Aquadex FlexFlow system includes a console, disposable blood set, and catheter. The company sells its products to hospitals and clinics through its direct salesforce in the United States.
- CEO
- Nestor Jaramillo
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 70
- Headquarters
- Minnesota
- Website
- nuwellis.com
Earnings
NUWE Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$2.4M↑ +26.2%
Diluted EPS-$2.19↓ -92.4%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $7.4M | $7.9M | $8.5M | $8.9M | $8.7M | $8.3M |
| Gross profit | $4.1M | $4.5M | $4.8M | $5.0M | $5.7M | $5.1M |
| Operating income | -$17.0M | -$19.5M | -$17.2M | -$17.6M | -$11.0M | -$11.1M |
| Net income | -$15.8M | -$19.6M | -$14.5M | -$20.2M | -$11.2M | -$17.5M |
| Diluted EPS | -$10.67 | -$285.36 | -$83.55 | -$360.06 | -$353.30 | -$25.39 |
| Operating cash flow | -$16.6M | -$17.8M | -$15.1M | -$17.9M | -$9.6M | -$10.8M |
| Free cash flow | -$16.9M | -$18.1M | -$15.3M | -$18.1M | -$9.7M | -$10.9M |
| Gross margin | 54.5% | 56.7% | 55.7% | 56.2% | 64.9% | 62.0% |
| Operating margin | -228.8% | -246.5% | -201.0% | -198.9% | -125.7% | -134.3% |
| Net margin | -212.8% | -246.9% | -170.0% | -228.0% | -127.7% | -211.9% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $2.4M | $2.3M | $1.9M | $1.7M | $2.2M | $2.4M | $2.4M |
| Gross profit | $1.5M | $1.7M | $1.4M | $1.1M | $958,000.00 | $1.4M | $1.7M | $1.7M |
| Operating income | -$2.3M | -$1.5M | -$2.4M | -$3.1M | -$2.9M | -$2.7M | -$2.4M | -$4.6M |
| Net income | -$7.7M | $2.4M | -$1.5M | -$3.0M | -$12.6M | $468,000.00 | -$2.4M | -$4.5M |
| Diluted EPS | -$791.82 | $73.23 | $389.40 | -$28.93 | -$60.99 | $0.56 | $63.97 | -$2.19 |
| Operating cash flow | -$2.8M | -$2.5M | -$1.5M | -$2.5M | -$2.1M | -$3.1M | -$3.0M | -$3.1M |
| Free cash flow | -$2.8M | -$2.5M | -$1.5M | -$2.5M | -$2.1M | -$3.2M | -$3.0M | -$3.1M |
| Gross margin | 67.2% | 70.0% | 58.4% | 56.0% | 55.5% | 65.2% | 68.2% | 70.1% |
| Operating margin | -105.7% | -64.7% | -102.8% | -160.7% | -168.5% | -121.7% | -100.8% | -190.1% |
| Net margin | -352.1% | 99.6% | -63.2% | -158.3% | -727.7% | 21.1% | -99.9% | -189.0% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.